COVID-19 Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0R8WT
|
|||
Drug Name |
Tocilizumab
|
|||
Synonyms |
Actemra; Actemra (TN); Tocilizumab (USAN/INN); Tocilizumab (genetical recombination); Tocilizumab (genetical recombination) (JAN); humanized IgG1 monoclonal antibody
|
|||
Drug Type |
Monoclonal antibody
|
|||
Indication | Coronavirus Disease 2019 (COVID-19) | Phase 3 | [1] | |
Other Indication | Giant cell arteritis | Approved | [2] | |
Therapeutic Class |
Antiviral Agents
|
|||
Company |
Roche; Genentech
|
|||
PubChem Substance ID |
Target | Top | |||
---|---|---|---|---|
Target(s) | HUMAN interleukin-6 receptor (IL6R) | Target Info | Inhibitor | [3] |
Interleukin-6, a type of protein released by the immune system, can trigger dangerous inflammatory cascades. Tocilizumab can ameliorate severe damage to lung tissue caused by cytokine release in patients with serious COVID-19 infections via inhibiting interleukin-6 receptor. |
References | Top | |||
---|---|---|---|---|
1 | ClinicalTrials.gov (NCT04320615) A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia. U.S. National Institutes of Health. | |||
2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
3 | Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report. Ann Oncol. 2020 Apr 2. pii: S0923-7534(20)36387-0. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.